One theory suggests that PTX3 overexpressed by tumors inhibits the complement system, potentially shielding tumor cells from immune detection [53] because, unlike in pathogen-bound states, fluid-phase PTX3 may block complement activation [89]. This evidence concerns the gene PTX3 and neoplasm.